2024
The relationship between childhood trauma, psychotic symptoms, and cognitive schemas in patients with schizophrenia, their siblings, and healthy controls: results from the EU-GEI study.
Üçok A, Noyan H, Gülöksüz S, Saka M, Alptekin K, Atbaşoğlu C, Akturan E, Karadayı G, Baran Tatar Z, Akdede B, Binbay T, Altınyazar V, Ulaş H, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Şahin Cankurtaran E, Ulusoy Kaymak S, Rutten B, van Os J. The relationship between childhood trauma, psychotic symptoms, and cognitive schemas in patients with schizophrenia, their siblings, and healthy controls: results from the EU-GEI study. Psychological Medicine 2024, 54: 2414-2425. PMID: 38606591, DOI: 10.1017/s0033291724000540.Peer-Reviewed Original ResearchNegative cognitive schemasChildhood traumaCognitive schemasPsychotic symptomsEU-GEIEmotional abuseBrief Core Schema ScalesEU-GEI studySubthreshold psychotic experiencesSubtypes of traumaChildhood emotional abuseChildhood Trauma QuestionnaireNon-clinical populationsHealthy controlsNegative schemasPositive symptomsPersecutory delusionsPsychotic experiencesSchema ScaleTrauma QuestionnaireChildhood abuseSymptom severitySchizophreniaSexual abuseAbuse
2023
Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation
van der Meer D, Cheng W, Rokicki J, Fernandez-Cabello S, Shadrin A, Smeland O, Ehrhart F, Gülöksüz S, Pries L, Lin B, Rutten B, van Os J, O’Donovan M, Richards A, Steen N, Djurovic S, Westlye L, Andreassen O, Kaufmann T, Aguilar E, Akdede B, Alptekin K, Altınyazar V, Amoretti S, Andric-Petrovic S, Arango C, Arrojo M, Atbaşoğlu C, Bernardo M, Binbay T, Bobes J, Cankurtaran E, Carracedo A, Cihan B, Delespaul P, García-Portilla M, González-Peñas J, Guloksuz S, Gümüş-Akay G, Jiménez-López E, Ulusoy Kaymak S, Kenis G, Lin B, López G, Luykx J, Maric N, Mezquida G, Mihaljevic M, Mirjanic T, Parellada M, Pries K, Rivero O, Rutten B, Saiz P, Can Saka M, Sanjuan J, Luis Santos J, Soygür H, Üçok A, Ulaş H, van Os J, Yalınçetin B, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, van Os J, Veling W. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation. Schizophrenia Bulletin 2023, 50: 327-338. PMID: 37824720, PMCID: PMC10919784, DOI: 10.1093/schbul/sbad140.Peer-Reviewed Original ResearchAge-matched healthy controlsBrain maturational processesIndependent clinical cohortsOnset of symptomsPolygenic riskCortical tissue samplesGenetic risk factorsDevelopment of schizophreniaHeritable brain disorderSymptom onsetHealthy controlsRisk factorsClinical cohortEarly neurodevelopmentPolygenic risk scoresRisk scoreImmune systemSchizophrenia diagnosisBrain disordersSchizophreniaNeuronal communicationStrong associationEarly adulthoodTissue samplesMaturational processesExamining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Prachason T, Erzin G, Pries L, Brondino N, Politi P, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Escarti M, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Üçok A, Alptekin K, Saka M, Arango C, O'Donovan M, van Os J, Rutten B, Guloksuz S, investigators G. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. Psychiatry Research 2023, 323: 115184. PMID: 37015164, DOI: 10.1016/j.psychres.2023.115184.Peer-Reviewed Original ResearchConceptsBenton Facial Recognition TestDegraded Facial Affect Recognition TaskWechsler Adult Intelligence Scale-Third EditionSchizophrenia spectrum disordersSocial cognitionCognitive domainsFacial affect recognition taskAffect recognition taskFacial Recognition TestCognitive impairmentRecognition testSpectrum disorderRecognition taskCross-sectional sampleHealthy controlsCognitionPsychosis spectrumShort versionUnaffected siblingsNeurocognitionEUGEI studySchizophreniaPerceptionImpairmentSiblingsAssociations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sampleThe association between exposome score for schizophrenia and metabolic parameters in individuals with schizophrenia and healthy controls: Findings from the EUGEI study
Erzin G, Atbaşoğlu C, Fusar-Poli L, Saka M, Üçok A, Alptekin K, Os J, Akay G, Gülöksüz S. The association between exposome score for schizophrenia and metabolic parameters in individuals with schizophrenia and healthy controls: Findings from the EUGEI study. European Psychiatry 2023, 66: s264-s264. PMCID: PMC10596217, DOI: 10.1192/j.eurpsy.2023.601.Peer-Reviewed Original ResearchMetabolic parametersHealthy controlsES-SCZHigh-density lipid levelsDiastolic blood pressureNational Schizophrenia NetworksExposome scorePhysical health outcomesBlood pressureAnalysis ageLipid levelsGlucose levelsGene-environment interactionsPsychosis developmentLinear regression analysisHealth outcomesPrenatal periodSchizophrenia NetworkSchizophreniaClinical implementationEnvironmental exposuresEUGEI studyNongenetic exposuresRegression analysisImportant metabolic parametersExamining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Findings from the EUGEI study
Fusar-Poli L, Investigators E, Investigators G, van Os J, Rutten B, Guloksuz S. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Findings from the EUGEI study. European Psychiatry 2023, 66: s445-s445. PMCID: PMC10434418, DOI: 10.1192/j.eurpsy.2023.957.Peer-Reviewed Original ResearchWechsler Adult Intelligence ScaleSchizophrenia spectrum disordersSocial cognitionFacial emotion recognition taskUnaffected siblingsEmotion recognition taskAdult Intelligence ScaleDisclosure of interestCognitive domainsIntelligence ScaleSpectrum disorderRecognition taskCognitionHealthy controlsNeurocognitionLongitudinal studyPresent cross-sectional studyEUGEI studyMolecular genetic riskSchizophreniaAssociations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly interventionThe association between exposome score for schizophrenia and metabolic parameters in individuals with schizophrenia and healthy controls
Erzin G, Atbaşoğlu C, Fusar-Poli L, Saka M, Üçok A, Alptekin K, Van Os J, Guloksuz S, Gümüş-Akay G. The association between exposome score for schizophrenia and metabolic parameters in individuals with schizophrenia and healthy controls. Neuroscience Applied 2023, 2: 103594. DOI: 10.1016/j.nsa.2023.103594.Peer-Reviewed Original Research
2022
The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.Peer-Reviewed Original ResearchConceptsHealthy controlsCannabis useDegraded Facial Affect Recognition TaskPresent cross-sectional studyCross-sectional studyHigh genetic riskProgression of schizophreniaRegular cannabis useCognitive disturbancesRegular cannabisPsychosis riskPatientsSchizophreniaFacial emotion recognition performanceGenetic riskCannabisCurrent cannabisEUGEI studyLongitudinal studyAgeSiblingsAssociationRiskOnsetEffect relationshipImpaired Effort Allocation in Patients with Recent-Onset Schizophrenia and Its Relevance to Negative Symptoms Assessments and Persistent Negative Symptoms
Guliyev E, Guloksuz S, Ucok A. Impaired Effort Allocation in Patients with Recent-Onset Schizophrenia and Its Relevance to Negative Symptoms Assessments and Persistent Negative Symptoms. Journal Of Clinical Medicine 2022, 11: 5060. PMID: 36078990, PMCID: PMC9457458, DOI: 10.3390/jcm11175060.Peer-Reviewed Original Research
2021
Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis
Oomen P, Begemann M, Brand B, de Haan L, Veling W, Koops S, van Os J, Smit F, Bakker P, van Beveren N, Boonstra N, Gülöksüz S, Kikkert M, Lokkerbol J, Marcelis M, Rosema B, de Beer F, Gangadin S, Geraets C, van ‘t Hag E, Haveman Y, van der Heijden I, Voppel A, Willemse E, van Amelsvoort T, Bak M, Batalla A, Been A, van den Bosch M, van den Brink T, Faber G, Grootens K, de Jonge M, Knegtering R, Kurkamp J, Mahabir A, Pijnenborg G, Staring T, Veen N, Veerman S, Wiersma S, Graveland E, Hoornaar J, Sommer I. Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis. Psychological Medicine 2021, 53: 2317-2327. PMID: 34664546, PMCID: PMC10123843, DOI: 10.1017/s0033291721004153.Peer-Reviewed Original ResearchConceptsDistinct cognitive subgroupsCognitive subgroupsFirst-episode psychosisDiscrete cognitive profilesGeneral functioningTrend-level effectsCognitive profileSelf-reported functional outcomesCognitive clustersCognitive deficitsCognitionBrief assessmentFunctional outcomeLarge sampleFEP patientsClinical outcomesCurrent resultsSevere clinical symptomsPsychosisEarly identificationHealthy controlsCluster analysisClinical symptomsFunctioningDeficitsExamining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, O'Donovan M, Rutten B, Guloksuz S. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2021, 113: 110440. PMID: 34536513, DOI: 10.1016/j.pnpbp.2021.110440.Peer-Reviewed Original ResearchConceptsDegraded Facial Affect Recognition TaskFacial emotion recognitionEmotion recognitionFacial affect recognition taskAffect recognition taskSocial cognition impairmentsFER deficitsIndividual emotionsPRS-SCZFER accuracyRecognition taskHealthy controlsSchizotypy-RevisedCognition impairmentIntermediate phenotypesPsychosis riskStructured interviewsEUGEI studySchizophreniaTotal scoreSiblingsGenetic riskDifferent patternsPsychosisEmotions
2020
Phenome-wide and genome-wide analyses of quality of life in schizophrenia
Pazoki R, Lin B, van Eijk K, Schijven D, de Zwarte S, Alizadeh B, van Amelsvoort T, Bartels-Velthuis A, van Beveren N, Bruggeman R, Cahn W, de Haan L, Delespaul P, Luykx J, Myin-Germeys I, Kahn R, Schirmbeck F, Simons C, van Os J, van Winkel R, Guloksuz S, Luykx J. Phenome-wide and genome-wide analyses of quality of life in schizophrenia. BJPsych Open 2020, 7: e13. PMID: 33295273, PMCID: PMC7791571, DOI: 10.1192/bjo.2020.140.Peer-Reviewed Original ResearchPolygenic risk scoresRisk scoreClinical phenotypeNon-genetic contributing factorsMajor depressive disorderQuality of lifeDepressive disorderHealthy controlsVulnerable patientsStudy populationHypothesis-generating approachPatientsPsychotic disordersQoLSmall studyClinical interventionsSchizophreniaGenotypic determinantsScoresContributing factorDisordersPhenotypeAssociationThiol/Disulfide Homeostasis in Bipolar and Unipolar Depression
Erzin G, Özkaya G, Topçuoğlu C, Yüksel R, Erel Ö, Yurt E, Göka E, Gülöksüz S. Thiol/Disulfide Homeostasis in Bipolar and Unipolar Depression. Clinical Psychopharmacology And Neuroscience 2020, 18: 395-401. PMID: 32702218, PMCID: PMC7383011, DOI: 10.9758/cpn.2020.18.3.395.Peer-Reviewed Original ResearchDisulfide/total thiol ratiosTotal thiol ratiosThiol-disulfide homeostasisBipolar depressionHealthy controlsUnipolar depressionNative thiol ratioBipolar disorderDisulfide levelsThiol ratioDepressive disorderNative thiolAnkara Numune TrainingThiol/disulfide homeostasisDisulfide/native thiol ratioOxidative stress markersUnipolar depressive disorderDSM-5 criteriaLevels of disulfideUD groupOutpatient clinicClinical entityDepressive episodeResearch HospitalTherapeutic differencesReduced regulatory T cells with increased proinflammatory response in patients with schizophrenia
Sahbaz C, Zibandey N, Kurtulmus A, Duran Y, Gokalp M, Kırpınar I, Sahin F, Guloksuz S, Akkoc T. Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia. Psychopharmacology 2020, 237: 1861-1871. PMID: 32221694, DOI: 10.1007/s00213-020-05504-0.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsRegulatory T cellsHealthy controlsT cellsIL-17AIL-6Smoking status-matched healthy controlsCulture supernatant levelsT cell percentageTh1/Th2Levels of Foxp3Blood mononuclear cellsBody mass indexImmune imbalanceTreg percentageMass indexProinflammatory cytokinesMethodsForty patientsMononuclear cellsPlasma levelsProinflammatory responseSupernatant levelsCell percentageResultsIn comparisonArray kit
2019
Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia
Sahbaz C, Özer O, Kurtulmus A, Kırpınar I, Sahin F, Guloksuz S. Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. Metabolic Brain Disease 2019, 34: 865-874. PMID: 30758707, DOI: 10.1007/s11011-019-00395-3.Peer-Reviewed Original ResearchConceptsBody mass indexSerum melatonin concentrationsPittsburgh Sleep Quality IndexHealthy controlsMelatonin concentrationsCognitive impairmentMorningness-Eveningness QuestionnaireHigher body mass indexLower MEQ scoresSleep Quality IndexNegative Syndrome ScaleEnzyme-linked immunosorbentCircadian preferenceMelatonin groupMass indexMelatonergic pathwaysHC groupPatientsNeurodevelopmental originSyndrome ScaleMelatonin levelsPatient samplesSchizophreniaMelatoninMEQ scores
2015
Temperament characteristics in patients with panic disorder and their first-degree relatives
Altınbaş G, Altınbaş K, Gülöksüz S, Gülöksüz S, Aydemir Ö, Özgen G. Temperament characteristics in patients with panic disorder and their first-degree relatives. Comprehensive Psychiatry 2015, 60: 73-77. PMID: 25967357, DOI: 10.1016/j.comppsych.2015.03.008.Peer-Reviewed Original ResearchConceptsFirst-degree relativesHealthy controlsPanic disorderIrritable temperament scoresPanic Agoraphobia ScaleAnxious temperament scoresTemperament characteristicsTrait Anxiety InventoryClinical characteristicsPatient groupClinical conditionsSan Diego AutoquestionnairePatientsTemperament scoresTrait markerAgoraphobia ScaleAnxiety disordersProspective designDisordersStudy sampleHeritable anxiety disordersAnxiety InventoryTemperament EvaluationEducation levelIntermediate phenotypes
2014
Electrocardiography changes in bipolar patients during long-term lithium monotherapy
Altinbas K, Guloksuz S, Caglar I, Caglar F, Kurt E, Oral E. Electrocardiography changes in bipolar patients during long-term lithium monotherapy. General Hospital Psychiatry 2014, 36: 694-697. PMID: 25091141, DOI: 10.1016/j.genhosppsych.2014.07.001.Peer-Reviewed Original ResearchConceptsTherapeutic serum levelsHealthy controlsSerum levelsLithium monotherapyLithium levelsEuthymic BD type I patientsBipolar disorderLong-term lithium useBD type I patientsCardiovascular side effectsChronic lithium treatmentSerum lithium levelsVentricular electrical instabilityType I patientsQT dispersion ratioUse of lithiumElectrocardiography changesI patientsBD patientsTherapeutic rangeLithium treatmentQRS intervalQT dispersionLithium useElectrocardiogram parameters
2013
P.2.h.002 Comparison of electrocardiogram parameters between lithium-well bipolar patients and healthy controls
Altinbas K, Guloksuz S, Caglar I, Caglar F, Kurt E, Oral E. P.2.h.002 Comparison of electrocardiogram parameters between lithium-well bipolar patients and healthy controls. European Neuropsychopharmacology 2013, 23: s416. DOI: 10.1016/s0924-977x(13)70658-8.Peer-Reviewed Original Research
2010
Cytokine levels in euthymic bipolar patients
Guloksuz S, Cetin E, Cetin T, Deniz G, Oral E, Nutt D. Cytokine levels in euthymic bipolar patients. Journal Of Affective Disorders 2010, 126: 458-462. PMID: 20537397, DOI: 10.1016/j.jad.2010.04.027.Peer-Reviewed Original ResearchConceptsEuthymic bipolar patientsBipolar patientsCytokine levelsHealthy controlsBipolar disorderDepressive episodeLithium monotherapyIL-10 levelsIL-4 levelsSerum cytokine levelsPro-inflammatory stateEffects of medicationNeuro-immune modulationTerms of agePatients 16Cytokine profileCytokine productionPresent studyIL-2IL-4IL-5Healthy volunteersPsychiatric disordersPatientsFlow cytometry